A PHP Error was encountered

Severity: Notice

Message: Undefined variable: title

Filename: libraries/Utilita.php

Line Number: 1011

Organigramma: scheda pubblicazioni

Maria Santoro

Fonte dei dati: Archivio della Ricerca http://art.torvergata.it
  1. Fokam, J., Ngoufack Jagni Semengue, E., Armenia, D., Takou, D., Dambaya, B., Teto, G., et al. (2022). High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in low and middle-income countries. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 102(2), 115574 [10.1016/j.diagmicrobio.2021.115574]. Dettagli
  2. Rusconi, S., Saladini, F., Bellocchi, M.C., Galli, L., Gagliardini, R., Gazzola, L., et al. (2022). Leronlimab (PRO 140) in vitro activity against 4-class drug resistant HIV-1 from heavily treatment experienced subjects. PHARMACOLOGICAL RESEARCH, 176, 106064 [10.1016/j.phrs.2022.106064]. Dettagli
  3. Armenia, D., Santoro, M., Bellocchi, M.C., Carioti, L., Galli, L., Galli, A., et al. (2022). Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 59(1), 106492 [10.1016/j.ijantimicag.2021.106492]. Dettagli
  4. Teto, G., Nka, A.D., Fokam, J., Bouba, Y., Takou, D., Fabeni, L., et al. (2022). Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients. SCIENTIFIC REPORTS, 12(1), 1374 [10.1038/s41598-022-05375-9]. Dettagli
  5. Sinopoli, A., Isonne, C., Santoro, M., & Baccolini, V. (2022). The effects of orally administered lactoferrin in the prevention and management of viral infections: A systematic review. REVIEWS IN MEDICAL VIROLOGY, 32(1), e2261 [10.1002/rmv.2261]. Dettagli
  6. Fokam, J., Mpouel Bala, M.L., Santoro, M., Takou, D., Tala, V., Beloumou, G., et al. (2021). Archiving of mutations in HIV-1 cellular reservoirs among vertically infected adolescents is contingent with clinical stages and plasma viral load: Evidence from the EDCTP-READY study. HIV MEDICINE [10.1111/hiv.13220]. Dettagli
  7. Bouba, Y., Armenia, D., Forbici, F., Bertoli, A., Borghi, V., Gagliardini, R., et al. (2021). Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(12), 3272-3279 [10.1093/jac/dkab322]. Dettagli
  8. Fokam, J., Takou, D., Njume, D., Pabo, W., Santoro, M., Njom Nlend, A., et al. (2021). Alarming rates of virological failure and HIV-1 drug resistance amongst adolescents living with perinatal HIV in both urban and rural settings: evidence from the EDCTP READY-study in Cameroon. HIV MEDICINE, 22(7), 567-580 [10.1111/hiv.13095]. Dettagli
  9. Scutari, R., Costabile, V., Galli, L., Bellocchi, M.C., Carioti, L., Barbaliscia, S., et al. (2021). Impact of analytical treatment interruption on burden and diversification of HIV peripheral reservoir: a pilot study. VIRUSES, 13(7) [10.3390/v13071403]. Dettagli
  10. Nka, A.D., Teto, G., Santoro, M., Ngum Ndze, V., Takou, D., Dambaya, B., et al. (2021). HIV-1 Gag gene mutations, treatment response and drug resistance to protease inhibitors: a systematic review and meta-analysis protocol. PLOS ONE, 16(7) [10.1371/journal.pone.0253587]. Dettagli
  11. Armenia, D., Bouba, Y., Gagliardini, R., Fabeni, L., Borghi, V., Berno, G., et al. (2021). Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice. HIV MEDICINE, 22(6), 519-525 [10.1111/hiv.13062]. Dettagli
  12. Lai, A., Franzetti, M., Bergna, A., Saladini, F., Bruzzone, B., Di Giambenedetto, S., et al. (2021). Marked decrease in acquired resistance to antiretrovirals in latest years in Italy. CLINICAL MICROBIOLOGY AND INFECTION, 27(7), 1038.e1-1038.e6-1038.e6 [10.1016/j.cmi.2020.09.028]. Dettagli
  13. Semengue, E., Armenia, D., Inzaule, S., Santoro, M., Dambaya, B., Takou, D., et al. (2021). Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(5), 1277-1285 [10.1093/jac/dkab004]. Dettagli
  14. Alkhatib, M., Di Maio, V.C., De Murtas, V., Polilli, E., Milana, M., Teti, E., et al. (2021). Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b. VIRUSES, 13(5), 743 [10.3390/v13050743]. Dettagli
  15. Lombardi, F., Giacomelli, A., Armenia, D., Lai, A., Dusina, A., Bezench, A., et al. (2021). Prevalence and factors associated with HIV-1 multidrug resistance over the past two decades in the Italian Arca database. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 57(2) [10.1016/j.ijantimicag.2020.106252]. Dettagli
  16. Mortari, E.P., Russo, C., Vinci, M.R., Terreri, S., Salinas, A.F., Piccioni, L., et al. (2021). Highly specific memory b cells generation after the 2nd dose of bnt162b2 vaccine compensate for the decline of serum antibodies and absence of mucosal iga. CELLS, 10(10), 2541 [10.3390/cells10102541]. Dettagli
  17. Galli, L., Parisi, M.R., Poli, A., Menozzi, M., Fiscon, M., Garlassi, E., et al. (2020). Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry. OPEN FORUM INFECTIOUS DISEASES, 7(11), ofaa456 [10.1093/ofid/ofaa456]. Dettagli
  18. Armenia, D., Bouba, Y., Gagliardini, R., Gori, C., Bertoli, A., Borghi, V., et al. (2020). Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings. JOURNAL OF CLINICAL VIROLOGY, 130, 104534 [10.1016/j.jcv.2020.104534]. Dettagli
  19. Saladini, F., Giannini, A., Giammarino, F., Maggiolo, F., Vichi, F., Corbelli, G.M., et al. (2020). In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(9), 2547-2553 [10.1093/jac/dkaa178]. Dettagli
  20. Canetti, D., Galli, L., Gianotti, N., Celotti, A., Calza, L., Gagliardini, R., et al. (2020). Simplification to High Genetic Barrier 2-Drug Regimens in People Living With HIV Harboring 4-Class Resistance Enrolled in the PRESTIGIO Registry. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 84(4), e24-e28 [10.1097/QAI.0000000000002378]. Dettagli
  21. Fokam, J., Takou, D., Semengue, E., Teto, G., Beloumou, G., Dambaya, B., et al. (2020). First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens. ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL, 9(1), 143 [10.1186/s13756-020-00799-2]. Dettagli
  22. Fokam, J., Takou, D., Teto, G., Nforbih, S.E., Kome, O.P., Santoro, M., et al. (2020). Pre-treatment drug resistance and HIV-1 genetic diversity in the rural and urban settings of Northwest-Cameroon. PLOS ONE, 15(7 July), e0235958 [10.1371/journal.pone.0235958]. Dettagli
  23. Santoro, M., Fornabaio, C., Malena, M., Galli, L., Poli, A., Menozzi, M., et al. (2020). Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 56(1) [10.1016/j.ijantimicag.2020.106027]. Dettagli
  24. Fokam, J., Nangmo, A., Wandum, C., Takou, D., Santoro, M., Nlend, A.N., et al. (2020). Programme quality indicators of HIV drug resistance among adolescents in urban versus rural settings of the centre region of Cameroon. AIDS RESEARCH AND THERAPY, 17(1), 14 [10.1186/s12981-020-00270-7]. Dettagli
  25. Semengue, E., Santoro, M., Ndze, V.N., Dambaya, B., Takou, D., Teto, G., et al. (2020). HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: a systematic review and meta-analysis protocol. SYSTEMATIC REVIEWS, 9(1), 93 [10.1186/s13643-020-01356-z]. Dettagli
  26. Bouba, Y., Berno, G., Fabeni, L., Carioti, L., Salpini, R., Aquaro, S., et al. (2020). Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(7), 1778-1786 [10.1093/jac/dkaa073]. Dettagli
  27. Armenia, D., Di Carlo, D., Flandre, P., Bouba, Y., Borghi, V., Forbici, F., et al. (2020). HIV MDR is still a relevant issue despite its dramatic drop over the years. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(5), 1301-1310 [10.1093/jac/dkz554]. Dettagli
  28. Soulie, C., Santoro, M.M., Storto, A., Abdi, B., Charpentier, C., Armenia, D., et al. (2020). Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY [10.1093/jac/dkz553]. Dettagli
  29. Artese, A., Svicher, V., Costa, G., Salpini, R., Di Maio, V.C., Alkhatib, M., et al. (2020). Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. DRUG RESISTANCE UPDATES, 53, 100721 [10.1016/j.drup.2020.100721]. Dettagli
  30. Fabeni, L., Santoro, M., Lorenzini, P., Rusconi, S., Gianotti, N., Costantini, A., et al. (2020). Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy. VIRUSES, 12(8), 791 [10.3390/v12080791]. Dettagli
  31. Scutari, R., Alteri, C., Vicenti, I., Carlo, D.D., Zuccaro, V., Incardona, F., et al. (2019). Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors. JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE [10.1016/j.jgar.2019.07.015]. Dettagli
  32. Alteri, C., Scutari, R., Stingone, C., Maffongelli, G., Brugneti, M., Falasca, F., et al. (2019). Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success. JOURNAL OF CLINICAL VIROLOGY, 117, 61-67 [10.1016/j.jcv.2019.06.004]. Dettagli
  33. Fabeni, L., Alteri, C., Berno, G., Scutari, R., Orchi, N., De Carli, G., et al. (2019). Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy. SEXUALLY TRANSMITTED INFECTIONS, 95(8), 619-625 [10.1136/sextrans-2019-054017]. Dettagli
  34. Armenia, D., Di Carlo, D., Cozzi-Lepri, A., Calcagno, A., Borghi, V., Gori, C., et al. (2019). Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen. ANTIVIRAL THERAPY, 24(5), 321-331. Dettagli
  35. Antinori, A., Santoro, M.m., Gagliardini, R., Marchetti, G., Mondi, A., Cento, V., et al. (2019). Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients. NEW MICROBIOLOGICA, 42(2), 69-80. Dettagli
  36. Alteri, C., Scutari, R., Bertoli, A., Armenia, D., Gori, C., Fabbri, G., et al. (2019). Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice. VIRUS GENES [10.1007/s11262-019-01649-z]. Dettagli
  37. Fokam, J., Sosso, S.M., Yagai, B., Billong, S.C., Djubgang Mbadie, R.E., Kamgaing Simo, R., et al. (2019). Viral suppression in adults, adolescents and children receiving antiretroviral therapy in Cameroon: Adolescents at high risk of virological failure in the era of "test and treat". AIDS RESEARCH AND THERAPY, 16(1), 36 [10.1186/s12981-019-0252-0]. Dettagli
  38. Pouga, L., Santoro, M.m., Charpentier, C., Di Carlo, D., Romeo, I., Artese, A., et al. (2019). New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T). CHEMICAL BIOLOGY & DRUG DESIGN, 93(1), 50-59 [10.1111/cbdd.13378]. Dettagli
  39. Rusconi, S., Santoro, M.m., Gianotti, N., Antinori, A., Bonora, S., Cingolani, A., et al. (2019). Is the rate of virological failure to cART continuing to decline in recent calendar years?. JOURNAL OF CLINICAL VIROLOGY, 116, 23-28 [10.1016/j.jcv.2019.04.009]. Dettagli
  40. Soulie, C., Santoro, M.M., Charpentier, C., Storto, A., Paraskevis, D., Di Carlo, D., et al. (2019). Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(3), 614-617 [10.1093/jac/dky464]. Dettagli
  41. Takou, D., Fokam, J., Teto, G., Santoro, M.-., Ceccherini-Silberstein, F., Nanfack, A.J., et al. (2019). HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: Evidence from routine clinical practice in Cameroon. BMC INFECTIOUS DISEASES, 19(1), 246 [10.1186/s12879-019-3871-0]. Dettagli
  42. Alteri, C., Fabeni, L., Scutari, R., Berno, G., Di Carlo, D., Gori, C., et al. (2018). Genetic divergence of HIV-1 B subtype in Italy over the years 2003–2016 and impact on CTL escape prevalence. SCIENTIFIC REPORTS, 8(1), 15739. Dettagli
  43. Raffaelli, C.S., Rossetti, B., Paglicci, L., Colafigli, M., Punzi, G., Borghi, V., et al. (2018). Impact of transmitted HIV-1 drug resistance on the efficacy of firstline antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(9), 2480-2484 [10.1093/jac/dky211]. Dettagli
  44. Armenia, D., Zaccarelli, M., Borghi, V., Gennari, W., Di Carlo, D., Giannetti, A., et al. (2018). Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment. JOURNAL OF CLINICAL VIROLOGY, 104, 61-64. Dettagli
  45. Fokam, J., Bellocchi, M.c., Armenia, D., Nanfack, A.j., Carioti, L., Continenza, F., et al. (2018). Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children. MEDICINE, 97(13), e0176 [10.1097/MD.0000000000010176]. Dettagli
  46. Santoro, M., Di Carlo, D., Armenia, D., Zaccarelli, M., Pinnetti, C., Colafigli, M., et al. (2018). Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice. ANTIVIRAL THERAPY, 23(3), 249-257 [10.3851/IMP3197]. Dettagli
  47. Fabeni, L., Berno, G., Fokam, J., Bertoli, A., Alteri, C., Gori, C., et al. (2017). Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains. JOURNAL OF CLINICAL MICROBIOLOGY, JCM.00656-17 [10.1128/JCM.00656-17]. Dettagli
  48. Armenia, D., Di Carlo, D., Maffongelli, G., Borghi, V., Alteri, C., Forbici, F., et al. (2017). Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens. HIV MEDICINE [10.1111/hiv.12388]. Dettagli
  49. Fabeni, L., Alteri, C., Di Carlo, D., Orchi, N., Carioti, L., Bertoli, A., et al. (2017). Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(10), 2837-2845 [10.1093/jac/dkx231]. Dettagli
  50. Rhee, S.-., Varghese, V., Holmes, S.P., Van Zyl, G.U., Steegen, K., Boyd, M.A., et al. (2017). Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. EBIOMEDICINE, 18, 225-235 [10.1016/j.ebiom.2017.03.024]. Dettagli
  51. Armenia, D., Di Carlo, D., Calcagno, A., Vendemiati, G., Forbici, F., Bertoli, A., et al. (2016). Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, dkw512 [10.1093/jac/dkw512]. Dettagli
  52. Alteri, C., Surdo, M., Di Maio, V., Di Santo, F., Costa, G., Parrotta, L., et al. (2016). The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate + emtricitabine-containing HAART both in vivo and in vitro. JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 7, 1-7 [10.1016/j.jgar.2016.06.005]. Dettagli
  53. De Luca, A., Flandre, P., Dunn, D., Zazzi, M., Wensing, A., Santoro, M.m., et al. (2016). Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIRaben-1 subtype B and non-subtype B receiving a salvage regimen. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(5), 1352-1360 [10.1093/jac/dkv465]. Dettagli
  54. Gregson, J., Tang, M., Ndembi, N., Hamers, R.L., Marconi, V.C., Brooks, K., et al. (2016). Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: A multicentre retrospective cohort study. THE LANCET INFECTIOUS DISEASES, 16(5), 565-575 [10.1016/S1473-3099(15)00536-8]. Dettagli
  55. Santoro, M.M., & Perno, C.F. (2016). Clinical relevance of genotypic resistance testing today. NEW MICROBIOLOGICA, 39(2), 91-92. Dettagli
  56. Di Maio, V., Cento, V., Di Paolo, D., Aragri, M., De Leonardis, F., Tontodonati, M., et al. (2016). HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(3), 739-750 [10.1093/jac/dkv403]. Dettagli
  57. Fokam, J., Takou, D., Santoro, M., Akonie, H., Kouanfack, C., Ceccherini Silberstein, F., et al. (2016). Short communication: Population-based surveillance of HIV-1 drug resistance in cameroonian adults initiating antiretroviral therapy according to the world health organization guidelines. AIDS RESEARCH AND HUMAN RETROVIRUSES, 32(4), 329-333 [10.1089/AID.2015.0065]. Dettagli
  58. Maffongelli, G., Alterib, C., Gentilotti, E., Bertoli, A., Ricciardi, A., Malagnino, V., et al. (2016). Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy. AIDS [10.1097/QAD.0000000000000977]. Dettagli
  59. Salpini, R., Fokam, J., Ceccarelli, L., Santoro, M., Nanfack, A., Sosso, S., et al. (2016). High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians. CURRENT HIV RESEARCH, 14(2), 165-171 [10.2174/1570162X13666150930114742]. Dettagli
  60. Zaccarelli, M., Santoro, M.m., Armenia, D., Borghi, V., Gennari, W., Gori, C., et al. (2016). Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA. JOURNAL OF CLINICAL VIROLOGY, 82, 94-100 [10.1016/j.jcv.2016.07.007]. Dettagli
  61. Andreoni, M., Marcotullio, S., Puro, V., De Carli, G., Tambussi, G., Nozza, S., et al. (2015). An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. NEW MICROBIOLOGICA, 38(4), 443-490. Dettagli
  62. Fabeni, L., Berno, G., Svicher, V., Ceccherini-Silberstein, F., Gori, C., Bertoli, A., et al. (2015). Genotypic tropism testing in HIV-1 proviral DNA can provide useful information at low-level viremia. JOURNAL OF CLINICAL MICROBIOLOGY, 53(9), 2935-2941 [10.1128/JCM.00893-15]. Dettagli
  63. Vingerhoets, J., Calvez, V., Flandre, P., Marcelin, A.-., Ceccherini Silberstein, F., Perno, C.F., et al. (2015). Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: An observational study using pooled European cohort data. HIV MEDICINE, 16(5), 297-306 [10.1111/hiv.12218]. Dettagli
  64. Armenia, D., Fabeni, L., Alteri, C., Di Pinto, D., Di Carlo, D., Bertoli, A., et al. (2015). HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(6), 1865-1873 [10.1093/jac/dkv029]. Dettagli
  65. Fabeni, L., Alteri, C., Orchi, N., Gori, C., Bertoli, A., Forbici, F., et al. (2015). Recent transmission clustering of HIV-1 C and CRF17-BF strains characterized by NNRTI-related mutations among newly diagnosed men in central Italy. PLOS ONE, 10(8), e0135325 [10.1371/journal.pone.0135325]. Dettagli
  66. Blanco, J.l., Montaner, J., Marconi, V.c., Santoro, M.m., Campos-Loza, A.e., Shafer, R.w., et al. (2014). Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy. AIDS, 28(17), 2531-2539 [10.1097/QAD.0000000000000424]. Dettagli
  67. Mirabelli, C., Surdo, M., Van Hemert, F., Lian, Z., Salpini, R., Cento, V., et al. (2014). Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection. JOURNAL OF INFECTION [10.1016/j.jinf.2014.10.015]. Dettagli
  68. Armenia, D., Soulie, C., Di Carlo, D., Fabeni, L., Gori, C., Forbici, F., et al. (2014). A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. PLOS ONE, 9(8) [10.1371/journal.pone.0105853]. Dettagli
  69. Svicher, V., Alteri, C., Santoro, M., Ceccherini-Silberstein, F., Marcelin, A., Calvez, V., et al. (2014). The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature. JOURNAL OF INFECTION [10.1016/j.jinf.2014.05.001]. Dettagli
  70. Santoro, M., Fabeni, L., Armenia, D., Alteri, C., Di Pinto, D., Forbici, F., et al. (2014). Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels. CLINICAL INFECTIOUS DISEASES, 58(8), 1156-1164 [10.1093/cid/ciu020]. Dettagli
  71. Santoro, M., Sabin, C., Forbici, F., Bansi, L., Dunn, D., Fearnhill, E., et al. (2013). Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. HIV MEDICINE, 841-845 [10.1111/hiv.12044]. Dettagli
  72. Alteri, C., Artese, A., Beheydt, G., Santoro, M., Costa, G., Parrotta, L., et al. (2013). Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 68(10), 2205-2209 [10.1093/jac/dkt173]. Dettagli
  73. Santoro, M., Armenia, D., Alteri, C., Flandre, P., Calcagno, A., Santoro, M., et al. (2013). Impact of pre-therapy viral load on virological response to modern first-line HAART. ANTIVIRAL THERAPY, 18(7), 867-876 [10.3851/IMP2531]. Dettagli
  74. Giuliani, M., Santoro, M., Lo Presti, A., Cella, E., Scognamiglio, P., Lai, A., et al. (2013). Circulation of HIV-1 CRF02_AG among MSM population in central Italy: a molecular epidemiology-based study. BIOMED RESEARCH INTERNATIONAL, 2013, 810617-810617. Dettagli
  75. Santoro, M., & Perno, C. (2013). HIV-1 Genetic Variability and Clinical Implications. ISRN MICROBIOLOGY, 2013, 481314-481314. Dettagli
  76. Svicher, V., Cento, V., Rozera, G., Abbate, I., Santoro, M., Armenia, D., et al. (2013). The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing. PLOS ONE, 8(1) [10.1371/journal.pone.0053603]. Dettagli
  77. Ciccozzi, M., Santoro, M., Giovanetti, M., Andrissi, L., Bertoli, A., & Ciotti, M. (2012). HIV-1 non-B subtypes in Italy: a growing trend. NEW MICROBIOLOGICA, 35(4), 377-386. Dettagli
  78. Santoro, M., Armenia, D., Fabeni, L., Santoro, M., Gori, C., Forbici, F., et al. (2012). The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients. CLINICAL MICROBIOLOGY AND INFECTION, 18(8) [10.1111/j.1469-0691.2012.03905.x]. Dettagli
  79. Ceccarelli, L., Salpini, R., Moudourou, S., Cento, V., Santoro, M., Fokam, J., et al. (2012). Characterization of drug resistance mutations in naive and ART-treated patients infected with HIV-1 in Yaounde, Cameroon. JOURNAL OF MEDICAL VIROLOGY, 84(5), 721-727 [10.1002/jmv.23244]. Dettagli
  80. Santoro, M.M., Alteri, C., Ronga, L., Flandre, P., Fabeni, L., Mercurio, F., et al. (2012). Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy. AIDS RESEARCH AND HUMAN RETROVIRUSES, 28(10), 1285-1293 [10.1089/aid.2011.0142]. Dettagli
  81. Alcaro, S., Alteri, C., Artese, A., Ceccherini-Silberstein, F., Costa, G., Ortuso, F., et al. (2011). Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine. CHEMMEDCHEM, 6(12), 2203-2213 [10.1002/cmdc.201100362]. Dettagli
  82. Alteri, C., Santoro, M.M., Abbate, I., Rozera, G., Bruselles, A., Bartolini, B., et al. (2011). 'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY [10.1093/jac/dkr354]. Dettagli
  83. Alteri, C., Santoro, M.M., Abbate, I., Rozera, G., Bruselles, A., Bartolini, B., et al. (2011). 'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY [doi: 10.1093/jac/dkr354]. Dettagli
  84. Fokam, J., Salpini, R., Santoro, M.M., Cento, V., Perno, C., Colizzi, V., et al. (2011). Drug Resistance Among Drug-naive and First-line Antiretroviral Treatment-failing Children in Cameroon. THE PEDIATRIC INFECTIOUS DISEASE JOURNAL [10.1097/INF.0b013e31822db54c]. Dettagli
  85. Ciccozzi, M., Vujošević, D., Lo Presti, A., Mugoša, B., Vratnica, Z., Lai, A., et al. (2011). Genetic diversity of HIV type 1 in Montenegro. AIDS RESEARCH AND HUMAN RETROVIRUSES, 27(8), 921-924 [10.1089/AID.2010.0323]. Dettagli
  86. Véras, N., Santoro, M.M., Gray, R.R., Tatem, A.J., Presti, A.L., Olearo, F., et al. (2011). Molecular Epidemiology of HIV Type 1 CRF02_AG in Cameroon and African Patients Living in Italy. AIDS RESEARCH AND HUMAN RETROVIRUSES [10.1089/AID.2010.0333]. Dettagli
  87. Fokam, J., Salpini, R., Santoro, M.M., Cento, V., D'Arrigo, R., Gori, C., et al. (2011). Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon. ARCHIVES OF VIROLOGY, 156(7), 1235-1243 [10.1007/s00705-011-0982-3]. Dettagli
  88. Ceccherini-Silberstein, F., Surdo, M., Alteri, C., Puertas, M.C., Saccomandi, P., Artese, A., et al. (2011). HIV-1 R5+ /X4- tropic viruses can be inhibited in vitro as well as in vivo by maraviroc: a refined analysis of patients enrolled in the Phase IIb study A4001029. Paper presented at International Workshop on HIV & Hepatitis virus Drug Resistance and curative strategies, Los Cabos, Mexico. Dettagli
    Ceccherini-Silberstein, F., Surdo, M., Alteri, C., Puertas, M.C., Saccomandi, P., Artese, A., et al. (2011). HIV-1 R5+ /X4- tropic viruses can be inhibited in vitro as well as in vivo by maraviroc: a refined analysis of patients enrolled in the Phase IIb study A4001029. Paper presented at International Workshop on HIV & Hepatitis virus Drug Resistance and curative strategies, Los Cabos, Mexico.
    Intervento a convegno
    Settore MED/07 - Microbiologia e Microbiologia Clinica
    Tutti gli Autori
    HIV-1 R5+ /X4- tropic viruses can be inhibited in vitro as well as in vivo by maraviroc: a refined analysis of patients enrolled in the Phase IIb study A4001029
    Ceccherini-Silberstein, F; Surdo, M; Alteri, C; Puertas, MC; Saccomandi, P; Artese, A; Balestra, E; Chapman, D; Lewis, M; Valdez, H; Clotet, B; Alcaro, S; Santoro, MM; Svicher, V; Martinez-Picado, J; Perno, CF
  89. Cento, V., Svicher, V., Rozera, G., Abbate, I., Santoro, M., Armenia, D., et al. (2011). The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing. Paper presented at 3th ICAR – Italian Conference on AIDS and Retroviruses, Firenze, Italia. Dettagli
  90. De Luca, A., Di Giambenedetto, S., Maserati, R., Gianotti, N., Narciso, P., Antinori, A., et al. (2011). Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score. ANTIVIRAL THERAPY, 16(4), 489-497 [10.3851/IMP1799]. Dettagli
  91. Santoro, M., Armenia, D., Fabeni, L., Santoro, M., Gori, C., Forbici, F., et al. (2011). The Lowest X4 Geno2Pheno-False Positive Rate Is Associated with Greater CD4-Depletion. Paper presented at 3th ICAR – Italian Conference on AIDS and Retroviruses, Firenze, Italia. Dettagli
  92. Svicher, V., Alteri, C., Artese, A., Forbici, F., Santoro, M.M., Schols, D., et al. (2010). Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 55(3), 336-344 [10.1097/QAI.0b013e3181e6763f]. Dettagli
  93. Svicher V, Alteri C, Artese A, Forbici F, Santoro MM, Schols D, et al. (2010). Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 55(3), 336-344 [doi: 10.1097/QAI.0b013e3181e6763f]. Dettagli
  94. Zehender, G., Ebranati, E., Lai, A., Santoro, M.M., Alteri, C., Giuliani, M., et al. (2010). Population dynamics of HIV-1 subtype B in a cohort of men-having-sex-with-men in Rome, Italy. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 55(2), 156-160. Dettagli
  95. Tommasi, C., Ceccherini-Silberstein, F., D'Arrigo, R., Bellagamba, R., Tempestilli, M., Dessì, C., et al. (2010). Use of novel antiretroviral agents in rescue regimens: a case of early virological failure to raltegravir. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 42(3), 237-239. Dettagli
  96. Zaccarelli, M., Antinori, A., Cozzi-Lepri, A., Mussini, C., Palamara, G., Santoro, M.M., et al. (2010). Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 53(1), 150-151. Dettagli
  97. Schapiro, J.M., Scherer, J., Boucher, C.A., Baxter, J.D., Tilke, C., Perno, C.F., et al. (2010). Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score. ANTIVIRAL THERAPY, 15(7), 1011-1019. Dettagli
  98. Santoro, M., Bertoli, A., Lorenzini, P., Ceccherini-Silberstein, F., Gianotti, N., Mussini, C., et al. (2009). Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients. INFECTION, 37(3), 233-243 [10.1007/s15010-008-8065-4]. Dettagli
  99. Giuliani, M., Montieri, S., Palamara, G., Latini, A., Alteri, C., Perno CF, et al. (2009). Non-B HIV type 1 subtypes among men who have sex with men in Rome, Italy. AIDS RESEARCH AND HUMAN RETROVIRUSES, 25(2), 157-164 [10.1089/aid.2008.0175]. Dettagli
  100. Trignetti, M., Sing, T., Svicher, V., Santoro, M., Forbici, F., D'arrigo, R., et al. (2009). Dynamics of NRTI resistance mutations during therapy interruption. AIDS RESEARCH AND HUMAN RETROVIRUSES, 25(1), 57-64 [10.1089/aid.2008.0159]. Dettagli
  101. Santoro, M., Ciccozzi, M., Alteri, C., Montieri, S., Alexiev, I., Dimova, I., et al. (2008). Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria. AIDS RESEARCH AND HUMAN RETROVIRUSES, 24(9), 1133-1138. Dettagli
  102. Svicher, V., Aquaro, S., D'Arrigo, R., Artese, A., Dimonte, S., Alcaro, S., et al. (2008). Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure. THE JOURNAL OF INFECTIOUS DISEASES, 197(10), 1408-1418 [10.1086/587693]. Dettagli
  103. Santoro, M., Bertoli, A., Lorenzini, P., Lazzarin, A., Esposito, R., Carosi, G., et al. (2008). Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study. AIDS PATIENT CARE AND STDS, 22(1), 7-16 [10.1089/apc.2007.0013]. Dettagli
  104. Ceccherini-Silberstein, F., Svicher, V., Sing, T., Artese, A., Santoro, M., Forbici, F., et al. (2007). Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors. JOURNAL OF VIROLOGY, 81(20), 11507-11519 [10.1128/JVI.00303-07]. Dettagli
  105. Aquaro, S., D'Arrigo, R., Svicher, V., Perri, G., Caputo, S., Visco-Comandini, U., et al. (2006). Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 58(4), 714-722 [10.1093/jac/dkl306]. Dettagli
  106. Svicher, V., Sing, T., Santoro, M., Forbici, F., Rodríguez-Barrios, F., Bertoli, A., et al. (2006). Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. JOURNAL OF VIROLOGY, 80(14), 7186-7198 [10.1128/JVI.02084-05]. Dettagli
  107. Santoro, M., Svicher, V., Gori, C., Zaccarelli, M., Tozzi, V., Forbici, F., et al. (2006). Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy. NEW MICROBIOLOGICA, 29(2), 89-100. Dettagli
  108. Ceccherini-Silberstein, F., Gago, F., Santoro, M., Gori, C., Svicher, V., Rodríguez-Barrios, F., et al. (2005). High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations. JOURNAL OF VIROLOGY, 79(16), 10718-10729 [10.1128/JVI.79.16.10718-10729.2005]. Dettagli
  109. Santoro, M., Ceccherini-Silberstein, F., Gori, C., Svicher, V., Forbici, F., Bellocchi, M., et al. (2004). Temporal change in the use of genotypic resistance testing over the years 1999--2003. NEW MICROBIOLOGICA, 27(2 Suppl 1), 141-144. Dettagli
  110. Buschini, A., Martino, A., Gustavino, B., Monfrinotti, M., Poli, P., Rossi, C., et al. (2004). Comet assay and micronucleus test in circulating erythrocytes of Cyprinus carpio specimens exposed in situ to lake waters treated with disinfectants for potabilization. MUTATION RESEARCH. GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 557, 119-129. Dettagli